Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy
Crossref DOI link: https://doi.org/10.1007/s10456-014-9438-1
Published Online: 2014-07-11
Published Print: 2014-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
de Haas, Sanne
Delmar, Paul
Bansal, Aruna T.
Moisse, Matthieu
Miles, David W.
Leighl, Natasha
Escudier, Bernard
Van Cutsem, Eric
Carmeliet, Peter
Scherer, Stefan J.
Pallaud, Celine
Lambrechts, Diether
Text and Data Mining valid from 2014-07-11